No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Female |
Gavage |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 1/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Male |
Gavage |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 18/50 25/50 22/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/50 2/50 2/49 COMBINED 18/50 27/50 24/49
|
Neoplastic Lesions
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Some Evidence |
Some Evidence |
LEUKEMIA 7/50 16/50 3/50
|
Neoplastic Lesions
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 3/50 7/49 4/50 OR CARCINOMA 1/50 5/49 0/50 COMBINED 4/50 12/49 4/50
|
Neoplastic Lesions
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Some Evidence |
Some Evidence |
ADENOMA 2/50 13/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Female |
Gavage |
Pituitary Gland
|
Some Evidence |
Some Evidence |
ADENOMA 15/49 24/50 25/50
|
Neoplastic Lesions
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Male |
Gavage |
Preputial Gland
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 4/50 4/50 OR CARCINOMA 1/50 2/50 1/50 COMBINED 1/50 6/50 5/50
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Adrenal Gland Medulla
|
Equivocal Evidence |
Equivocal Evidence |
benign, malignant, or complex pheochromocytoma (1/86, 9/89, 5/87, 4/88)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Brain
|
Equivocal Evidence |
Equivocal Evidence |
glioma malignant (0/90, 3/90, 0/90, 0/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Brain
|
Clear Evidence |
Clear Evidence |
glioma malignant (0/90, 0/90, 0/90, 3/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Heart
|
Equivocal Evidence |
Equivocal Evidence |
schwannoma malignant (0/90, 2/90, 0/90, 2/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Heart
|
Clear Evidence |
Clear Evidence |
schwannoma malignant (0/90, 2/90, 3/90, 6/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Liver
|
Clear Evidence |
Equivocal Evidence |
hepatocellular adenoma or carcinoma (combined) (0/90, 2/90, 4/89, 1/88)
|
May Have Been Related
|
Yes
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Pituitary Gland
|
Clear Evidence |
Equivocal Evidence |
pars distalis, adenoma (17/89, 25/90, 34/90, 13/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
benign, malignant, or complex pheochromocytoma (11/88, 24/90, 28/89, 14/87)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Brain
|
Clear Evidence |
Equivocal Evidence |
meninges, granular cell tumor benign or malignant (1/90, 3/90, 4/90, 3/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Brain
|
Clear Evidence |
Clear Evidence |
glioma malignant (0/90, 3/90, 3/90, 2/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Heart
|
Equivocal Evidence |
Equivocal Evidence |
schwannoma malignant (0/90, 0/90, 2/90, 0/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Heart
|
Clear Evidence |
Clear Evidence |
schwannoma malignant (0/90, 2/90, 1/90, 5/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Pancreas Islet Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma (13/90, 27/89, 19/86, 16/85)
|
May Have Been Related
|
Yes
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Pituitary Gland
|
Clear Evidence |
Equivocal Evidence |
pars distalis, adenoma (17/89, 28/90, 26/90, 26/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Prostate Gland
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma (2/90, 2/90, 7/90, 3/90)
|
May Have Been Related
|
No
|
TR-545
|
446-72-0 |
Endocrine disruptor (Genistein) |
Rats |
Sprague Dawley |
Male |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-545
|
446-72-0 |
Endocrine disruptor (Genistein) |
Rats |
Sprague Dawley |
Female |
Dosed-Feed |
Mammary Gland
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR ADENOCARCINOMA 7/53 8/49 11/50 13/50
|
May Have Been Related
|
No
|
TR-545
|
446-72-0 |
Endocrine disruptor (Genistein) |
Rats |
Sprague Dawley |
Female |
Dosed-Feed |
Mammary Gland
|
Some Evidence |
Some Evidence |
ADENOMA OR ADENOCARCINOMA 9/54 4/50 8/50 16/49
|
Neoplastic Lesions
|
Yes
|
TR-545
|
446-72-0 |
Endocrine disruptor (Genistein) |
Rats |
Sprague Dawley |
Female |
Dosed-Feed |
Pituitary Gland
|
Some Evidence |
Some Evidence |
ADENOMA OR CARCINOMA 38/54 32/49 40/50 44/50
|
Neoplastic Lesions
|
Yes
|
TR-545
|
446-72-0 |
Endocrine disruptor (Genistein) |
Rats |
Sprague Dawley |
Female |
Dosed-Feed |
Pituitary Gland
|
Some Evidence |
Some Evidence |
ADENOMA OR CARCINOMA 38/54 40/50 34/50 46/49
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 9/50 2/50 33/50; CARCINOMA 2/50 29/50 47/50
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/49 16/50 9/50; CARCINOMA 13/49 19/50 45/50
|
Neoplastic Lesions
|
Yes
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Pituitary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/47 19/49 26/49; CARCINOMA 1/47 0/49 0/49
|
Neoplastic Lesions
|
Yes
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Pituitary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/44 0/42 8/41
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 35/50 CARCINOMA 0/50 0/50 8/50
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/49 26/50 CARCINOMA 1/50 0/49 5/50
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 6/44 28/49 CARCINOMA 2/50 1/44 8/49
|
Neoplastic Lesions
|
No
|
TR-388
|
96-45-7 |
Ethylene thiourea (ETU) |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 9/46 23/50 CARCINOMA 1/49 3/46 26/50
|
Neoplastic Lesions
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/49 2/50 5/49
|
May Have Been Related
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Some Evidence |
Some Evidence |
ADENOMA 6/50 8/40 13/50 OR CARCINOMA 0/50 0/40 1/50 COMBINED 6/50 8/40 14/50
|
Neoplastic Lesions
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Some Evidence |
Some Evidence |
LEUKEMIA 14/50 29/50 24/50
|
Neoplastic Lesions
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Rats |
F344/N |
Male |
Gavage |
Nasal Cavity
|
Some Evidence |
Equivocal Evidence |
ADENOMA 0/48 0/47 2/49
|
May Have Been Related
|
Yes
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Mice |
B6C3F1 |
Female |
Gavage |
Pituitary Gland
|
Some Evidence |
Some Evidence |
ADENOMA 10/47 15/45 24/46
|
Neoplastic Lesions
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
CARCINOMA 0/49 5/49 1/49
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 5/50 7/49 32/50 46/49 hepatocellular carcinoma 4/50 2/49 6/50 27/49 hepatocellular adenoma or carcinoma 8/50 8/49 33/50 47/49
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 23/50 35/50 49/50 40/50 hepatocellular carcinoma 18/50 15/50 30/50 45/50 hepatocellular adenoma or carcinoma 31/50 40/50 49/50 47/50 hepatoblastoma 1/50 1/50 16/50 5/50 hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma 31/50 40/50 49/50 47/50
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
cholangiocarcinoma 0/50 0/49 0/50 2/47 hepatocholangioma 0/50 0/49 0/50 8/47 hepatocellular adenoma 3/50 2/49 8/50 16/47 hepatocellular carcinoma 0/50 0/49 1/50 6/47 hepatocellular adenoma or carcinoma 3/50 2/49 8/50 17/47) hepatocholangioma, hepatocellular adenoma, or hepatocellular carcinoma 3/50 2/49 8/50 21/47
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma or carcinoma 3/49 2/50 4/50 9/50; hepatocholangioma, hepatocellular adenoma, or hepatocellular carcinoma 3/49 2/50 4/50 11/50
|
Neoplastic Lesions
|
Yes
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Male |
Gavage |
Pituitary Gland
|
Clear Evidence |
Clear Evidence |
(pars distalis): adenoma 19/49 12/49 22/50 35/50
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 1/45 3/45 2/48 6/46
|
Neoplastic Lesions
|
No
|
TR-589
|
32534-81-9 |
Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] |
Rats |
Wistar Han |
Female |
Gavage |
Uterus
|
Clear Evidence |
Equivocal Evidence |
stromal polyp or stromal sarcoma (original and residual evaluations, combined) 4/50 12/50 12/50 9/49
|
May Have Been Related
|
No
|
TR-235
|
17924-92-4 |
Zearalenone |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-235
|
17924-92-4 |
Zearalenone |
Rats |
F344/N |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-235
|
17924-92-4 |
Zearalenone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
ADENOMA 0/50 2/49 7/49
|
Neoplastic Lesions
|
Yes
|
TR-235
|
17924-92-4 |
Zearalenone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Pituitary Gland
|
Positive |
Positive |
ADENOMA 3/46 2/43 13/42
|
Neoplastic Lesions
|
Yes
|
TR-235
|
17924-92-4 |
Zearalenone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Pituitary Gland
|
Positive |
Positive |
ADENOMA 0/40 4/45 6/44
|
Neoplastic Lesions
|